{"url_path":"/sec/mbrx/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-017034-index.html","accession_number":"0001437749-26-017034","cik":"0001659617","ticker":"MBRX","issuer_name":"Moleculin Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-017034-index.html","primary_entity_key":"0001659617","primary_entity_name":"Moleculin Biotech, Inc."},"word_count":133,"has_tables":true,"body_markdown":"**ITEM 5. OTHER INFORMATION**\n\n \n\nDuring the period covered by this Quarterly Report, none of the Company’s directors or executive officers has adopted or terminated a Rule *10b5*-*1* trading arrangement or a non-Rule *10b5*-*1* trading arrangement (each as defined in Item *408* of Regulation S-K under the Securities Exchange Act of *1934,* as amended).\n\n \n\nOn *May 6, 2026,*we agreed to issue warrants to purchase *100,000* shares of common stock with an exercise price of *$2.48* per share to an entity providing consulting services, which warrants will vest in *12* equal monthly installments over *one* year, subject to the entity's continued provision of consulting services to the Company. The warrant was issued pursuant to the exemption from the registration requirements of the Securities Act of *1933* available under Section *4*(a)(*2*) thereunder.\n\n \n\n18\n\n[Table of Contents](#toc)"}